Çocukluk Çağında Migren
Özet
Pediatrik yaş grubunda baş ağrısı, sıklığı yaşla birlikte artan ve genellikle iyi seyirli olan yaygın bir klinik durumdur. Baş ağrıları, altta yatan nedene göre primer ve sekonder olarak iki ana başlıkta sınıflandırılırken, tanı sürecinde detaylı anamnez ve nörolojik muayene belirleyicidir. Özellikle ciddi patolojilere işaret eden "kırmızı bayrak" bulgularının varlığında nörogörüntüleme gibi ileri tetkikler zorunluluk arz eder. Migren gibi primer baş ağrılarının yönetiminde ise hem yaşam tarzı düzenlemeleri hem de gerektiğinde farmakolojik tedaviler etkin rol oynar.
Headaches in the pediatric population are increasingly common and typically follow a benign, self-limiting course. These conditions are broadly classified as primary or secondary based on their etiology, with clinical history and neurological examination serving as the cornerstones of diagnosis. Advanced imaging is generally reserved for cases presenting with "red flag" symptoms that suggest underlying organic pathology. Effective management strategies for primary headaches, such as migraine, rely on a combination of lifestyle modifications and appropriate pharmacological interventions.
Referanslar
Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study.Cephalalgia. 2010 Sep 30;9:1065-72.
MacGregor EA. In the clinic. Migraine. Ann Intern Med. 2013 Nov 5;159:ITC5-1-15.
Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012 Oct 30;79:1881-8.
Ducros A, Tournier-Lasserve E, Bousser MG. The genetics of migraine. Lancet Neurol. 2002 Sep 1;5:285-93.
Qubty W, Patniyot I. Migraine Pathophysiology. Pediatr Neurol. 2020 Jun;107:1-6.
Parsons AA, Whalley ET. Characterization of the 5-hydroxytryptamine receptor which mediates contraction of the human isolated basilar artery. Cephalalgia. 1989 Sep 9;9:47-51.
Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013 May 12;5:454-61.
Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia. 1996 Aug 16;5:310-6.
Fan PC, Kuo PH, Chang SH, Lee WT, Wu RM, Chiou LC. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia. 2009 Aug 29;8:883-90.
Gursoy-Ozdemir Y, Qiu J, Matsuoka N,et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004 May 113;10:1447-55.
Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhouri M, Lee ML, Chugani HT. Increased brain serotonin synthesis in migraine. Neurology. 1999 Oct 22;53:1473-9.
Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhouri M, Lee ML, Chugani HT. Increased brain serotonin synthesis in migraine. Neurology. 1999 Oct 22;53:1473-9.
Sarısoy S, Aydın ÖF, Sungur M, et al. The relationship between migraine and right-to-left shunt in children. Eur J Pediatr. 2011 Mar 170;3:365-70.
McCandless RT, Arrington CB, Nielsen DC, Bale JF Jr, Minich LL. Patent foramen ovale in children with migraine headaches. J Pediatr. 2011 Aug 159;2:243-7.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan 38;1:1-211.
Goadsby PJ, Holland PR, Martins-Oliveira M Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 Apr 97;2:553-622
Cuvellier JC, Mars A, Vallée L. The prevalence of premonitory symptoms in paediatric migraine: a questionnaire study in 103 children and adolescents. Cephalalgia. 2009 Nov 29;11:1197-201.
Karsan N, Bose P, Goadsby PJ. The Migraine Premonitory Phase. Continuum (Minneap Minn). 2018 Aug 24;4:996-1008.
Viana M, Linde M, Sances G, et al. Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia. 2016 Apr 36;5:413-21
Kissoon NR, Cutrer FM. Aura and Other Neurologic Dysfunction in or with Migraine. Headache. 2017 Jul 57;7:1179-1194.
Hansen JM, Lipton RB, Dodick DW, et al. Migraine headache is present in the aura phase: a prospective study. Neurology. 2012 Nov 13;79:2044-9.
Dooley JM, Pearlman EM. The clinical spectrum of migraine in children.Pediatr Ann. 2010 Jul;39(7):408-15.
Gelfand AA, Reider AC, Goadsby PJ. Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. Neurology. 2013 Jul 81;5:431-6.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007 May 27;5:394-402
Finocchi C, Sivori G. Food as trigger and aggravating factor of migraine. Neurol Sci. 2012 May;33;1:77-80.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55:754-62.
Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004 Sep 56;3:371-81.
Patniyot I, Qubty W. Short-term Treatment of Migraine in Children and Adolescents. JAMA Pediatr. 2020 Aug 1;174:789-790.
Evans RW. Concomitant triptan and SSRI or SNRI use: what is the risk for serotonin syndrome? Headache. 2008 Apr 48;4:639-40.
Wolters Kluwers. Pathophysiology, clinical manifestations, and diagnosis of migraine in adults (24.06.2021 tarihinde https://www.uptodate.com/contents/pathophysiology-clinical-manifestations-and-diagnosis-of-migraine-in- adresinden ulaşılmıştır)
Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012 Jun 129;6:1411-20.
Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 5th ed. Philadelphia, PA: Elsevier Health; 2015
Talai A, Heilbrunn B. Ondansetron for Acute Migraine in the Pediatric Emergency Department. Pediatr Neurol. 2020 Feb 103:52-56.
Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020
Lewis DW, Winner P. The pharmacological treatment options for pediatric migraine: an evidence-based appraisal. NeuroRx. 2006 Apr 3;2:181-91.
Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, andImplementation Subcommittee of the AmericanAcademy of Neurology and the American Headache Society. Neurology. 2019 Sep 10;93:500-509.
O’Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012 May 13;7:959-66.
Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J; Topiramate Pediatric Migraine Study Investigators. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005 Nov-Dec 45;10:1304-12.
Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009 Mar 123;3:924-34.
O’Brien HL, Kabbouche MA, Hershey ADExpert Opin Pharmacother. Treating pediatric migraine: an expert opinion. 2012 May 13;7:959-66.
Locher C, Kossowsky J, Koechlin H, et al. Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis: A Systematic Review and Network Meta-analysis. JAMA Pediatr. 2020 Apr 1;174(4):341-349.
Sorge F, De Simone R, Marano E, Nolano M, Orefice G, Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988 Mar 8;1:1-6.
Asghar SJ, Milesi-Hallé A, Kaushik C, Glasier C, Sharp GB. Variable manifestations of familial hemiplegic migraine associated with reversible cerebral edema in children. Pediatr Neurol. 2012 Sep 47;3:201-4.
Szperka CL, VanderPluym J, Orr SL, et al. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache. 2018 Nov 58;10:1658-1669.
